SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Annual Wellness Visit, Subsequent — Pablo Neruda

PatientPablo Neruda
Date of birth1959-07-12
IdentifiersMRN HR-ML051-SYN; SSN (made up) 000-51-2976
Document date2026-10-05
AuthorMarisol Fairweather-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Subsequent annual wellness visit; no new complaints. [S]

History of Present Illness

Mr. Neruda returns for his subsequent annual wellness visit, with a professional Spanish interpreter; his first was with his previous physician last year. He completed the health risk assessment in Spanish beforehand. He is three weeks past his second leuprolide injection and continues apalutamide; radiotherapy to the prostate finished six weeks ago. The rash has gone. Hot flashes come four or five times a day and wake him once or twice a night; he would rather not take a medicine for them yet. His energy is lower in the afternoons, and he rests after lunch. He has no bone pain, has had no falls, and walks most afternoons. He writes every morning and has kept his official duties, apart from a week of engagements put off during radiotherapy. His interest in sex has fallen, as he was told it might; he has thought about it and does not want treatment for it now. [S]

ElementDetail
VisitSubsequent annual wellness visit
Safety eventsNo falls, emergency visits or hospital stays in the past year; one sick visit for a drug rash
MedicinesLeuprolide 22.5 mg every twelve weeks; apalutamide 240 mg daily; amlodipine 10 mg daily; cholecalciferol 2000 units daily; denosumab 60 mg every six months
Active conditionsMetastatic hormone-sensitive prostate cancer on androgen deprivation with apalutamide; hypertension; prediabetes; low bone mass
Functional statusIndependent in all activities and instrumental activities of daily living

Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]

DomainFinding
Self-rated healthFair to good
PsychosocialWriting every morning; close to his wife and friends; worry about the cancer at times, manageable
TobaccoNever used tobacco
Alcohol and drugsWine with dinner a few evenings a week (AUDIT-C 2); no other drug use
Physical activityWalks 30 minutes most afternoons; light resistance exercise twice a week, begun for bone and muscle on androgen deprivation
NutritionMany official dinners; dairy, fish and greens for calcium; weight up 2.2 kg since starting treatment
SleepHot flashes wake him once or twice a night; rests after lunch
Activities of daily livingIndependent
Instrumental activities of daily livingIndependent; manages his own medicines with a weekly pill box
Home safetySmoke detectors working; rugs secured; good lighting on the stairs
FallsNo falls; no fear of falling
Hearing and visionReading glasses; eye examination last year; hearing good
MemoryNo concerns
PainNone

Review of Systems

SystemResultFinding
ConstitutionalPositiveLower afternoon energy on androgen deprivation; weight up 2.2 kg; no fever or night sweats
EyesNegativeNo change in vision
Ears, nose, mouth, and throatNegativeNo hearing change; no mouth sores
CardiovascularNegativeNo chest pain, palpitations or leg swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeBowels back to normal after radiotherapy; no bleeding
GenitourinaryPositiveNocturia once; stream better; lower libido and erections
MusculoskeletalNegativeNo bone or joint pain
IntegumentaryNegativeRash resolved
NeurologicalNegativeNo weakness, numbness or unsteadiness
PsychiatricNegativeMood steady; PHQ-2 score 0
EndocrinePositiveHot flashes four or five times a day; no breast tenderness

12 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-04-06 to 2026-07-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-07-13activeS
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone painTwo tablets up to three times daily as neededOral route2026-06-01 to 2026-09-14completedS
Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without foodOne tablet once dailyOral route2026-06-15activeS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeksOne injection every twelve weeksIntramuscular route2026-06-22activeS
Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet dailyOne tablet dailyOral route2026-06-15activeS
Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivationOne injection every six monthsSubcutaneous route2026-07-13activeS
Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin)Twice daily for two weeksTopical route2026-08-10 to 2026-08-24completedS
Cetirizine 10 mg oral tablet, one tablet daily for itchOne tablet dailyOral route2026-08-10 to 2026-08-31completedS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-10-05activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-05Body height178cmS
2026-10-05Body weight94.6kgS
2026-10-05Body mass index (BMI) [Ratio]29.9kg/m2S
2026-10-05Systolic blood pressure128mm[Hg]S
2026-10-05Diastolic blood pressure78mm[Hg]S
2026-10-05Heart rate70/minS
2026-10-05Respiratory rate14/minS
2026-10-05Body temperature36.6CelS
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-05Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-05Total score [Mini-Cog]5{score}S
2026-10-05Total score [AUDIT-C]2{score}S

Physical Exam

Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell and engaged; weight 94.6 kg, BMI 29.9; blood pressure 128/78
EyesNear vision 20/30 with reading glasses
EarsWhispered-voice test passed on both sides
NeckNo thyroid enlargement; no lymph nodes
CardiovascularRegular rhythm at 70 per minute; no murmur; no ankle swelling
RespiratoryClear
ChestMild gynecomastia without tenderness
AbdomenSoft and non-tender
MusculoskeletalNo spinal or pelvic tenderness; Timed Up and Go 9 seconds; rises from a chair without using his arms
NeurologicalStrength and sensation normal in the legs; gait steady; Mini-Cog 5 of 5
PsychiatricEuthymic, thoughtful; judgment and insight intact
SkinRash resolved without scarring; no suspicious lesions

Problems

ProblemClinical statusVerificationCodeProvenance
Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmedresolvedconfirmed R97.20S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer.
Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971activeconfirmed C61S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read.
Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites.
Pelvic lymph node metastases: right external iliac and right obturator nodesactiveconfirmed C77.5S — Synthetic nodal disease.
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognitionactiveconfirmed Z79.899S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
Essential hypertension for five years, on amlodipineactiveconfirmed I10S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure.
Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL)activeconfirmed E55.9S — Synthetic finding at intake, addressed at the second visit.
Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis)activeconfirmed M85.89S — Synthetic bone-health finding on the DXA before androgen deprivation.
Prediabetes (hemoglobin A1c 5.9%)activeconfirmed R73.03S — Synthetic metabolic finding at intake, relevant to androgen deprivation.
Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamideresolvedconfirmed L27.0S — Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim.
Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit)activeconfirmed Z92.3S — Synthetic: recorded after the course of radiotherapy finished.
Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observationactiveconfirmed R94.6S — Synthetic finding; raised TSH is a known effect of apalutamide.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Influenza vaccineCompleted todayHigh-dose vaccine given today
COVID-19 vaccineCompleted todayThis season's vaccine given today
Pneumococcal vaccineCompleted todayPCV20 given today; no earlier pneumococcal vaccine; no further doses needed
Recombinant zoster vaccineDueNever given; dose 1 at the next visit, as he wanted no more than three injections today
RSV vaccineNot indicatedUnder 75 without a chronic heart, lung, kidney or immune condition that raises his risk; to be reviewed at 75 or if that changes
Tetanus, diphtheria and pertussis boosterUp to dateTdap six years ago; next in four years
Colorectal cancer screeningUp to dateNormal colonoscopy seven years ago; next due in three years
Abdominal aortic aneurysm screeningNot indicatedRecommended for men 65 to 75 who have ever smoked; he never smoked
Lung cancer screeningNot indicatedNever smoker
Hepatitis C screeningUp to dateOne-time screening negative eight years ago
Cholesterol and statin decisionCompleted today10-year ASCVD risk about 17 percent; atorvastatin 20 mg started after discussion
Diabetes screeningUp to dateHemoglobin A1c 6.1 percent three weeks ago (prediabetes); repeat yearly on androgen deprivation
Bone densityUp to dateDXA four months ago; denosumab every six months; repeat DXA in one to two years
Depression screeningCompleted todayPHQ-2 score 0
Unhealthy alcohol use screeningCompleted todayAUDIT-C score 2, low risk
Cognitive assessmentCompleted todayMini-Cog 5 of 5
Falls preventionCompleted todayTimed Up and Go 9 seconds; no falls; apalutamide raises fall risk, so resistance and balance exercise continue
Skin checkCompleted todayNo suspicious lesions

Immunizations given today: High-dose influenza vaccine, this season; COVID-19 vaccine, mRNA, this season; Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Adult Immunization Schedule by Age (2026)

Follow-up: Zoster vaccine dose 1 and blood pressure check in six weeks, with a lipid panel, ALT, TSH and free T4. Medical oncology and the next leuprolide injection in nine weeks. Next annual wellness visit in one year. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 30 minutes, in Spanish with a professional interpreter, with his consent. He named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is to keep writing, to be told the truth about his illness in his own language, and to make his own decisions. He chose not to record specific treatment preferences today and will review the plan with his oncologist and with this clinic yearly or if his health changes. [S]